Shares of Outlook Therapeutics (OTLK) were up Friday after the biopharmaceutical company reported a loss of $4.06 per share for fiscal 2024, narrowing from a loss of $4.72 a year earlier.
Six analysts surveyed by FactSet estimated a loss of $4.91 per share.
The company didn't report any revenue for the year ended Sept. 30.
Price: 1.96, Change: +0.26, Percent Change: +15.35
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.